CG Oncology, Inc. Common stock (CGON) NASDAQ
67.48
+0.69(+1.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
67.48
+0.69(+1.03%)
Currency In USD
| Previous Close | 66.79 |
| Open | 65.99 |
| Day High | 68.4 |
| Day Low | 65.97 |
| 52-Week High | 69.35 |
| 52-Week Low | 14.8 |
| Volume | 1.28M |
| Average Volume | 1.34M |
| Market Cap | 5.7B |
| PE | -32.44 |
| EPS | -2.08 |
| Moving Average 50 Days | 58.96 |
| Moving Average 200 Days | 41.67 |
| Change | 0.69 |
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
GlobeNewswire Inc.
Feb 27, 2026 1:30 PM GMT
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) N
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annua
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
GlobeNewswire Inc.
Jan 09, 2026 1:30 PM GMT
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermedia
Data not available